Bright Minds Biosciences Inc. (CSE: DRUG | NASDAQ: DRUG) announced on November 2, 2026, that the U.S. Food and Drug Administration has placed its investigational new drug application for Developmental and Epileptic Encephalopathies on a partial clinical hold, pausing its planned Phase 2 trial of BMB-101 in the United States. The FDA cited identified toxicity in mice and insufficient pharmacokinetic and juvenile toxicity data to support the proposed pediatric enrollment. The company states the hold does not affect its other ongoing clinical trials, a distinction investors may be watching closely.

Key Points

  • Bright Minds Biosciences Inc. (CSE: DRUG | NASDAQ: DRUG) is a biotechnology company developing treatments for neurological and psychiatric disorders.
  • The FDA has placed a partial clinical hold on the company's IND for DEEs and Protocol BMB-101-105, halting the planned U.S. Phase 2 trial.
  • The FDA stated it will provide a full Partial Clinical Hold Letter within 30 days; the company intends to immediately request further clarification.
  • Investors will be watching whether the company can resolve the FDA's concerns and lift the hold to allow future U.S. trials to proceed.

FDA Partial Clinical Hold Targets Planned BMB-101 Phase 2 DEE Trial

The FDA notified Bright Minds via email that the IND for DEEs and its associated protocol have been placed on a partial clinical hold following the agency's review. The planned trial was designed as a randomized, placebo-controlled, double-blind Phase 2 study to evaluate the efficacy and safety of ascending doses of BMB-101, up to a maximum tolerated dose, for seizures associated with DEEs. The company stated its belief that the hold covers only this specific planned U.S. Phase 2 trial and does not affect the company's other ongoing clinical programs.

Mouse Toxicity Findings Drive FDA's Stated Concerns About Pediatric Enrollment

The primary reason provided by the FDA relates to toxicity identified in mice, combined with inadequate pharmacokinetic and juvenile toxicity data to support the proposed enrollment of pediatric patients. The company stated its belief, based on toxicity reports, peer reviewers, and multiple independent toxicology expert opinions, that the adverse mouse findings were incidental and not drug-related. The company also noted its belief that the toxicity observed in mice was not seen in any other species. The announcement explicitly states these are the company's beliefs and do not represent the FDA's findings or resolve its stated concerns.

BMB-101 Prior Clinical Data and the BREAKTHROUGH Trial Results

Bright Minds has completed two clinical trials with BMB-101, with approximately 90 subjects having received the compound across all clinical programs. In a Phase 1 study of 64 healthy volunteers, BMB-101 was reported as well tolerated with no drug-related serious adverse events. Topline data from the Phase 2 BREAKTHROUGH trial, announced January 6, 2026, showed that in 24 adults with drug-resistant absence seizures or DEE, six DEE patients who completed the main study treatment experienced a median reduction of motor seizures of 63.3%, with all five DEE patients who entered the open-label extension remaining on therapy.

Company Response and Path to Resolving the Clinical Hold

Bright Minds stated it intends to immediately request further clarification from the FDA and plans to review the forthcoming full Partial Clinical Hold Letter, expected within 30 days, which will include additional details, non-hold recommendations, and study-design recommendations. The company indicated it would refine the study in accordance with FDA recommendations to address the identified issues. The announcement cautions that additional data or studies may be required, and that there is no assurance as to when or whether the partial clinical hold will be lifted or future U.S. trials will be permitted to proceed.